Predictors of Individual Response to Placebo or Tadalafil 5mg among Men with Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: An Integrated Clinical Data Mining Analysis.
A significant percentage of patients with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) achieve clinically meaningful improvement when receiving placebo or tadalafil 5mg once daily. However, individual patient characteristics associated with treatment response a...
Main Authors: | Ferdinando Fusco, Gianluca D'Anzeo, Carsten Henneges, Andrea Rossi, Hartwig Büttner, J Curtis Nickel |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4540425?pdf=render |
Similar Items
-
Evaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication
by: Ali Hamidi Madani, et al.
Published: (2012-02-01) -
Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride
by: Kirill V. Kosilov, et al.
Published: (2020-06-01) -
Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia
by: Chris Olesovsky, et al.
Published: (2016-08-01) -
Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action
by: Osamu Yokoyama, et al.
Published: (2015-10-01) -
Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies
by: O'Leary Michael P, et al.
Published: (2010-11-01)